Acetyl Hexapeptide-8 vs Palmitoyl Tetrapeptide-7
A side-by-side research comparison of Acetyl Hexapeptide-8 and Palmitoyl Tetrapeptide-7 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Acetyl Hexapeptide-8 | Palmitoyl Tetrapeptide-7 |
|---|---|---|
| Full name | Acetyl Hexapeptide-8 (Argireline Advanced) | Palmitoyl Tetrapeptide-7 (Pal-GQPR) |
| Category | Skin & Anti-Aging | Skin & Anti-Aging |
| Status | Research compound | Research compound |
| Mechanism | Same SNARE complex competition as argireline with acetyl modification for improved stability and cellular uptake. | Inhibits IL-6 release from keratinocytes and reduces inflammation-mediated MMP activation, preserving existing collagen while complementing Pal-GHK collagen building. |
| Molecular weight | 889 Da | 693 Da |
| Half-life | 10-14 hours | 8-12 hours (topical) |
| Bioavailability | Improved (topical, acetylated) | Good (topical) |
| Typical dose | 5-10% | 2-4% in formulation |
| Frequency | 2x daily | 1-2x daily |
| Route | Topical | Topical |
Acetyl Hexapeptide-8 reported benefits
- Improved stability
- Expression wrinkle reduction
- Preventative anti-aging
- Compatible with most formulations
Palmitoyl Tetrapeptide-7 reported benefits
- Anti-inflammatory (skin)
- Reduces IL-6
- Prevents collagen degradation
- Combats inflammaging
Related comparisons
Research and educational reference only. Not medical advice.